Wedbush reaffirmed their outperform rating on shares of Adherex Technologies (TSE:FRX) in a research note issued to investors on Monday, March 12th. Wedbush also issued estimates for Adherex Technologies’ Q4 2017 earnings at ($0.15) EPS, FY2017 earnings at ($0.56) EPS, Q1 2018 earnings at ($0.16) EPS, Q2 2018 earnings at ($0.17) EPS, Q3 2018 earnings at ($0.17) EPS, Q4 2018 earnings at ($0.19) EPS, FY2018 earnings at ($0.72) EPS, FY2020 earnings at $0.43 EPS, FY2021 earnings at $1.11 EPS and FY2022 earnings at $2.95 EPS.
FRX has been the subject of several other reports. HC Wainwright restated a buy rating on shares of Adherex Technologies in a research report on Tuesday, February 20th. Laidlaw began coverage on shares of Adherex Technologies in a research note on Wednesday, November 29th. They issued a buy rating and a C$22.00 price target for the company.
TSE:FRX traded up C$1.24 during midday trading on Monday, hitting C$17.90. The company had a trading volume of 17,350 shares, compared to its average volume of 2,517. Adherex Technologies has a 52-week low of C$4.11 and a 52-week high of C$18.24.
Adherex Technologies (TSE:FRX) last announced its earnings results on Monday, March 26th. The biopharmaceutical company reported C($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of C($0.17) by C($0.02).
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/07/fennec-pharmaceuticals-frx-outperform-rating-reiterated-at-wedbush.html.
Adherex Technologies Company Profile
Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, a water soluble thiol compound that acts as a chemical reducing agent, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.
Receive News & Ratings for Adherex Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adherex Technologies and related companies with MarketBeat.com's FREE daily email newsletter.